PI-LAB-2026-057

PT-141, Independent Lab Report

PT-141 5mg · NextGen Peptides

Verified

Independent testing verdict Pass

This product matched its label.

Identity confirmed and measured purity of 98.5% met the stated ≥99% claim. Content measured 100.1% of label.

Identity verified
Yes

Mass spectrometry confirmed the labelled compound

Measured purity
98.5%

Label claimed ≥99%

Content accuracy
100%

5mg measured against 5mg claimed

Test recency
Current cycle

Published 3 months ago

Specimen PI-LAB-2026-057 Tested by Chelsea Analytical Group 17 samples tested from this company Purity & Testing score 91/100

Full laboratory evidence Findings table, methodology, chain of custody and the original report

Findings

Metric Label claim Measured Assessment
Purity (HPLC) ≥ 99% 98.5% Within analytical tolerance
Identity (MS) PT-141 Confirmed Matches label
Content 5 mg 5 mg Within 5% of label

Methodology & chain of custody

RP-HPLC purity with electrospray ionisation mass confirmation.

The sample was purchased anonymously through standard retail checkout and shipped to an unaffiliated address, then logged, photographed, and forwarded under chain-of-custody documentation to Chelsea Analytical Group. See our full testing methodology.

Lot / batch
L2202-26
Purchased
Analysed
Published
Laboratory
Chelsea Analytical Group
Test type
Purity & identity

Original laboratory report: PI-LAB-2026-057-report.pdf (document delivery arrives with the production storage backend)

More Tests, NextGen Peptides

Retatrutide
Purity 99.7% Verified
Tirzepatide/Cagrilintide Blend
Purity 97.6% Verified
Tirzepatide
Purity 98.2% Discrepancy

More Tests, PT-141

PT-141 BioRegen Research
Purity 95.1% Verified
PT-141 Helix Research Supply
Purity 97.6% Discrepancy
PT-141 Quantum Peptide Group
Purity 96.8% Verified